Cerulean Closes Public Offering of Common Stock

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. CVS
10. SPY

Go back to Cerulean Closes Public Offering of Common Stock

Cerulean Pharma (CERU) Announces Publication of Positive CRLX101 Data

April 13, 2015 7:14 AM EDT

Cerulean Pharma (Nasdaq: CERU) announced the publication of a manuscript in Breast Cancer Research and Treatment, describing preclinical data that demonstrate CRLX101, Ceruleans lead proprietary investigational drug, targets breast cancer stem cells and impedes resistance to anti-angiogenic therapy in breast cancer mouse models.

The results of the study demonstrate that CRLX101, a dual topoisomerase-1 and HIF-1 inhibitor, blocks the HIF-1 mediated increase in cancer stem cells induced by Avastin® (bevacizumab) in a triple-negative breast cancer xenograft... More